China
Africa
Explore chapters and articles related to this topic
Treatment of Psychological Disorders
Published in Mohamed Ahmed Abd El-Hay, Understanding Psychology for Medicine and Nursing, 2019
Reboxetine is a selective noradrenergic reuptake inhibitor (NARI). Although weight gain and sedation are unusual with reboxetine, insomnia, anxiety, agitation, sexual dysfunction, and side effects similar to tricyclics, such as urinary retention, dry mouth, hypotension, and constipation can occur. Also like the tricyclics, reboxetine is contra-indicated in those with closed-angle glaucoma. Because its mode of action is complementary to SSRIs, it is possible to use reboxetine in combination with one of these drugs in chronic depression or where there is partial response to a serotonergic agent.
Psychiatric disorders
Published in Anne Lee, Sally Inch, David Finnigan, Therapeutics in Pregnancy and Lactation, 2019
There are few published data on the outcome of pregnancies exposed to paroxetine, sertraline, citalopram, fluvoxamine, venlafaxine, nefazadone, mirtazepine and reboxetine so their use in pregnancy cannot be supported.
Pharmacological management of depression in older people
Published in Stephen Curran, John P Wattis, Practical Management of Affective Disorders in Older People, 2018
Stephen Curran, Andrew Byrne, John P Wattis
There is limited evidence that reboxetine has benefit in older people with depression and causes less hypotension and fewer serious side-effects than TCAs.49 However, renal clearance is reduced in older patients.50 The pharmacokinetics of reboxetine are linear following both single and multiple oral doses and the plasma half-life is approximately 12 hours. Metabolism is mainly via the liver with only 10% cleared by the kidneys but plasma concentrations are increased in older patients.
Choosing among second-generation antidepressant treatments for depressed patients with cardiac diseases
Published in International Journal of Psychiatry in Clinical Practice, 2019
Clinical experience with reboxetine in patients affected by serious concomitant systemic illnesses is limited. According to the SmPC of the compound, orthostatic hypotension has been observed at doses higher than the maximum recommended, so a particular attention should be paid when administering reboxetine with other drugs known to lower blood pressure.
Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management
Published in Expert Opinion on Drug Safety, 2022
Joan Winter, Kimberly Curtis, Bo Hu, Anita H. Clayton
Reboxetine is a selective norepinephrine reuptake inhibitor with negligible effect on 5-HT and no effect on dopamine reuptake. Evidence suggests its association with SD is similar to placebo[90]. For unclear reasons, this effect may be more relevant to female patients[91].